10-Q: Turnstone Biologics Reports Q2 2024 Financial Results and Provides Clinical Update

Turnstone Biologics reports a net loss of $40.9 million for the first half of 2024, while highlighting positive preliminary data from its TIDAL-01 clinical trial.

Summary

• Turnstone Biologics, a clinical-stage biotechnology company, reported a net loss of $40.9 million for the six months ended June 30, 2024, compared to a net loss of $21.4 million for the same period in 2023.
• The company's operating expenses increased to $42.7 million for the first half of 2024, up from $41.5 million in the first half of 2023, primarily driven by increased manufacturing costs.
• Research and development expenses totaled $33.5 million for the first half of 2024, compared to $32.9 million for the same period in 2023.
• The company had cash, cash equivalents, and short-term investments of $62.4 million as of June 30, 2024, down from $94.8 million at the end of 2023.
• Turnstone is developing next-generation TIL therapies, with its lead candidate, TIDAL-01, currently in Phase 1 clinical trials.
• Preliminary data from the first four evaluable patients in the TIDAL-01 multi-site trial showed a 25% overall response rate and a 50% disease control rate in advanced colorectal cancer.
• The company has a revolving credit facility of up to $20 million with Banc of California, subject to certain conditions, including achieving positive interim Phase 1 data for TIDAL-01 and securing $40 million in new funding by March 31, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for 12 months after the filing of the financial statements, dependent on raising additional funding.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there are positive clinical trial results, the significant increase in net loss, the decrease in cash reserves, and the going concern warning from management create a negative outlook. The need for a capital raise adds further uncertainty.

Positives

• The company reported a 25% overall response rate and a 50% disease control rate in the first four evaluable patients in the TIDAL-01 multi-site trial for advanced colorectal cancer.
• One patient in the TIDAL-01 trial achieved an ongoing complete response and has been progression-free for over a year.
• The company has secured a revolving credit facility of up to $20 million with Banc of California.
• The company has secured additional dedicated cleanroom capacity at Moffitt's on-site cGMP facility for manufacturing of TIDAL-01.

Negatives

• The company incurred a net loss of $40.9 million for the first half of 2024, a significant increase from the $21.4 million loss in the same period of 2023.
• The company's cash, cash equivalents, and short-term investments decreased to $62.4 million as of June 30, 2024, from $94.8 million at the end of 2023.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The company's operating expenses increased to $42.7 million for the first half of 2024, up from $41.5 million in the first half of 2023.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding.
• The company may not be able to secure additional financing in a timely manner or on favorable terms.
• The company's business is highly dependent on the success of its lead product candidate, TIDAL-01.
• Clinical development is a lengthy and expensive process with uncertain outcomes.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• Negative developments in the fields of immuno-oncology and TIL-based immunotherapy could damage public perception of the company's product candidates.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or failures.
• The regulatory approval process is lengthy, time-consuming, and unpredictable.
• The company's intellectual property may not be adequately protected.
• The company's stock price may be volatile.

Future Outlook

The company plans to continue advancing its clinical trials for TIDAL-01, develop TIDAL-02, and evaluate the combination of TIDAL-01 with viral immunotherapy. The company expects to incur significant expenses and increasing operating losses for the foreseeable future as it continues its research and development programs.

Management Comments

• Management's cash flow forecasts indicate that based on the company's expected future operating losses and negative cash flows, there is substantial doubt about the company's ability to continue as a going concern for 12 months after the date the unaudited consolidated financial statements are filed with the SEC.
• Management intends to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.

Industry Context

The company is operating in the competitive biotechnology and pharmaceutical industries, specifically in the field of immuno-oncology and TIL-based therapies. The company's approach to selecting and expanding tumor-reactive T cells is a differentiated approach to the treatment of solid tumors.

Comparison to Industry Standards

• The reported 25% overall response rate in the TIDAL-01 trial for advanced colorectal cancer is notable, as the current standard of care treatment provides an ORR of 1 to 6% in this patient population.
• The company's approach to TIL therapy is differentiated from other approaches that rely on standard bulk TILs, which have shown objective responses in clinical trials only in limited tumor types.
• The company's focus on selecting and expanding the most potent tumor-reactive T cells is based on work conducted in academia that has demonstrated improved clinical responses for selected TILs in solid tumor types where bulk TILs have not shown benefit.
• The company is leveraging this work to establish a standardized manufacturing process for large scale production of its Selected TILs.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need to raise additional capital.
• Employees may be affected by potential reductions in spending or restructuring if the company is unable to secure additional funding.
• Patients may benefit from the development of new therapies, but clinical trial results are still preliminary.
• Suppliers and creditors may face potential delays in payments if the company's financial situation worsens.

Next Steps

• The company intends to provide the next clinical update for the TIDAL-01 multi-site trial in the first half of 2025.
• The company plans to continue advancing its preclinical pipeline programs, including TIDAL-02 and the TIDAL-01 viral immunotherapy combination program.
• The company intends to raise additional capital through equity offerings, debt financings or other capital sources.

Key Dates

Keywords

TIL therapy, immunotherapy, cancer, clinical trials, TIDAL-01, biotechnology, oncology, drug development, cell therapy, biologics